Puma Biotechnology Inc at JPMorgan Healthcare Conference Transcript
All right. We're going to get started. Up next, we have Puma Biotechnology.
With that, Chairman and CEO Alan Auerbach, take it from here.
Great. Thank you. Just a reminder that I'll be making forward-looking statements.
So on this slide, you can see Puma's product pipeline. It consists of the drug neratinib, which we have tested across a number of different indications and is also on the market as well. As you can see, the drug is marketed in the U.S., Europe and a number of other countries in extended adjuvant HER2-positive breast cancer. We also have it in testing in metastatic breast cancer, in metastatic breast cancer with brain mets and then in a certain subset of breast cancer patients that have a genetic mutation in HER2.
So first, talk about the commercial aspects of our business. We currently sell neratinib, which is a brand name
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
